.png)
If your health system operates in Kansas, you may believe you have state-level protection against manufacturer restrictions on contract pharmacy arrangements. As of right now, that protection is functionally in question, and the fix has been stuck in the state legislature for over a year.
Kansas enacted a law in 2024 prohibiting drugmakers from restricting 340B drug delivery to contract pharmacies, taking effect July 1, 2024, after Governor Laura Kelly vetoed a legislative provision that would have delayed it. On paper, Kansas joined the growing list of states with contract pharmacy access protections.
Then, in March 2025, the Kansas Attorney General determined that the state's existing law was unenforceable. That determination, not a court ruling or a legislative repeal, is what actually undermined the law's force. In direct response, the Kansas Senate passed a strengthened replacement bill, SB 284, on March 20, 2025, by emergency final action. The bill would authorize the State Board of Pharmacy to investigate complaints and impose discipline, including suspension or revocation of registration, against entities that unlawfully restrict 340B drug delivery.
SB 284 was referred to two House committees in late March 2025 and has not moved since. Because Kansas runs on a two-year legislative cycle, the bill technically remained alive into the 2026 session rather than dying at year's end. That gave it a second chance at a floor vote.
It didn't get one. In March 2026, the Kansas House Speaker abruptly ended the legislative session, a maneuver that blocked a scheduled floor vote on the bipartisan bill. Separately, in January 2026, House lawmakers introduced a different bill focused specifically on hospital 340B reporting requirements, distinct from the contract pharmacy access question SB 284 addresses. As of the most recent reporting we could verify, SB 284 remains stalled in the House, with no confirmed vote scheduled.
We also found a secondary reference describing Kansas's original law as having "expired" on June 30, 2026. We could not confirm this against Kansas's own legislative records or a primary source, and it doesn't square cleanly with the unenforceability determination and stalled-bill narrative above. We're flagging this rather than asserting it, and would treat any specific expiration date for the 2024 law as unconfirmed until verified directly with Kansas legislative staff or your state hospital association.
Separate from the legislative fight, there's a concrete, dated fact worth your attention: manufacturer channel tracking shows Kansas is no longer treated as exempt from at least one major manufacturer's 340B contract pharmacy restriction policy, effective July 1, 2026. In plain terms, a manufacturer that had previously carved Kansas out of its restrictions, likely because the 2024 state law appeared to require it, stopped doing so as of that date.
That is the practical consequence of the Attorney General's unenforceability determination playing out in real time. When a state's own top legal officer says a contract pharmacy protection law can't be enforced, manufacturers have little reason to keep voluntarily complying with it. Kansas covered entities should not assume any manufacturer exemption tied to the 2024 law is still in effect for every product or every manufacturer without checking directly.
Check your active manufacturer restriction notices specifically for Kansas. Don't rely on last year's list. If a manufacturer had exempted Kansas from a contract pharmacy restriction policy, confirm that exemption is still active today, not just at the start of this year.
Don't rely on the 2024 state law as your primary protection. With the state's own Attorney General having determined it unenforceable, treat any contract pharmacy arrangement in Kansas as though it rests on federal law and manufacturer-specific policy, not on the state statute.
Watch SB 284, but don't wait on it. It's the most likely path to a real fix, but it has now been stalled for over a year through two separate legislative maneuvers. Build your compliance and access planning around the assumption that it may not pass this cycle.
Loop in your state hospital association. Kansas Hospital Association and similar groups are typically the fastest source of on-the-ground updates when House leadership acts unpredictably, as it did in March 2026.
We track state-level 340B legislation and cross-reference it against manufacturer-specific restriction policies, because the two don't always move together, and a law on the books doesn't guarantee a manufacturer will honor it. For Kansas specifically, that means watching both SB 284's status and each manufacturer's current exemption list, rather than assuming either one reflects the full picture on its own.
Is Kansas's 2024 contract pharmacy law still technically in effect? It hasn't been repealed, but the Kansas Attorney General determined in March 2025 that it's unenforceable. That's a significant practical difference from a law being struck down in court or repealed by the legislature, but the effect on covered entities may be similar.
What would SB 284 change if it passes? It would authorize the State Board of Pharmacy to investigate complaints and discipline entities, including suspension or revocation of registration, for unlawfully restricting 340B drug delivery, giving the state a real enforcement mechanism it currently lacks.
Why did the House Speaker end the session before a vote? Sources describe it as a maneuver to block a floor vote on the bipartisan bill, without detailing the stated rationale. We'd recommend checking directly with Kansas legislative sources for the Speaker's own explanation before characterizing the motivation in anything you publish.
Does this affect all manufacturers the same way? No. Manufacturer contract pharmacy restriction policies are set individually. Kansas's exemption status varies by manufacturer, and at least one major manufacturer's channel tracking shows Kansas's exemption ending July 1, 2026. Check each manufacturer's current policy directly rather than assuming a uniform status across your portfolio.
